Everolimus improves progression-free survival for patients with advanced, nonfuctional neuroendocrine tumors

In an international Phase III randomized study, everolimus, an inhibitor of the mammalian target of rapamycin, has shown to dramatically improve progression-free survival for patients with advanced, nonfunctional neuroendocrine tumors of the lung and gastrointestinal tract.